



## **INDIA'S DRUG PRICING AUTHORITY ISSUES REVISED CEILING PRICES AND NEW RETAIL PRICES FOR NUMEROUS DRUGS**

The National Pharmaceutical Pricing Authority (**NPPA**), through an order dated 07 February 2025, has revised the ceiling prices for two scheduled formulations in accordance with the Drugs (Prices Control) Order, 2013 (**DPCO**). This price revision follows the Wholesale Price Index (**WPI**) adjustment of 0.00551% for the year 2024. The drugs impacted by this order are Azithromycin (Tablet 250 mg) and Amoxicillin + Clavulanic Acid (Powder for Injection 1g + 200 mg). Manufacturers of these drugs are required to update their pricing in line with the newly fixed ceiling prices, exclusive of goods and services tax (**GST**), where applicable.

As part of the compliance process, manufacturers must issue a revised price list reflecting the changes in pricing for the above-mentioned drugs and submit it to the NPPA, State Drug Controllers, and the dealers.

In a separate order issued on the same date, 07 February 2025, the NPPA has fixed retail prices for 42 new drugs under the DPCO. Manufacturers and marketing companies are now required to comply with these newly fixed retail prices, exclusive of GST. Manufacturers currently selling these drugs at prices below the prescribed ceiling can continue to do so, while those selling above the ceiling price must reduce their prices to adhere to the DPCO order. Furthermore, manufacturers are required to submit a price list in Form V to the NPPA, State Drug Controller, and dealers.

### **Read more at:**

1. <https://www.nppaindia.nic.in/uploads/tender/56776e2b66d582618ef9ba84385d6425.pdf>
2. <https://www.nppaindia.nic.in/uploads/tender/3c49b81b67d1e85d4cd97096a74f7135.pdf>



*This is only for general informational purposes and shall not be construed to constitute legal advice (which can only be given after being formally engaged and familiarizing ourselves with all the relevant facts). Should you have any queries, or require any assistance or clarifications with regard to anything contained in this newsletter, please feel free to contact our Partner, Mr. Pradnesh Warke.*

## The Team



### PRADNESH WARKE

Partner

Email – [p.warke@luthra.com](mailto:p.warke@luthra.com)



### RAVI RAJ SHEKHAR

Associate



### TANAY JHA

Associate



#### NEW DELHI

1st and 9th Floors, Ashoka Estate,  
24 Barakhamba Road, New Delhi - 110 001  
T: +91 11 4121 5100 F: +91 11 2372 3909  
E: [delhi@luthra.com](mailto:delhi@luthra.com)



#### MUMBAI

20th Floor, Indiabulls Finance Center,  
Tower 2 Unit A2, Elphinstone Road,  
Senapati Bapat Marg, Mumbai - 400 013  
T: +91 22 4354 7000  
F: +91 22 6630 3700  
E: [mumbai@luthra.com](mailto:mumbai@luthra.com)



#### BENGALURU

3rd Floor, Onyx Centre, No. 5, Museum Road,  
Bengaluru - 560 001  
T: +91 80 4112 2800 / +91 80 4165 9245  
F: +91 80 4112 2332  
E: [bengaluru@luthra.com](mailto:bengaluru@luthra.com)



#### HYDERABAD

Serene Towers,  
House No. 8-2-623/A,  
Road No. 10, Banjara Hills,  
Hyderabad, Telangana - 500034  
T: +91 40 7969 6162  
E: [hyderabad@luthra.com](mailto:hyderabad@luthra.com)



#### CHENNAI

Prestige Palladium Bayan,  
8th Floor, Greams Road, Nungambakkam Division,  
Egmore, Chennai - 600 006,  
Tamil Nadu  
T: +91 95604 88155  
E: [chennai@luthra.com](mailto:chennai@luthra.com)